Coronary/Structural Heart

HeartStitch® GmbH Announces NobleStitch™ EL Closure Data Compared to Published PFO Clinical Trials “RESPECT” and “CLOSURE” in New England Journal of Medicine

FRANKFURT, Germany, Oct. 6, 2017 /PRNewswire/ — Prof. Dr. Achille Gaspardone, Director of Cardiology at Hospital of Sant’Eugenio (Rome, Italy) presented a comprehensive report on closure of PFO (Patent Foramen Ovale) utilizing the NobleStitch™ EL suture based closure system at the CSI-UCSF meeting on Congenital Structural Interventions in San Francisco.  The NobleStitch™ EL, […]

BIOTRONIK Announces First Enrollments to BIOVITESSE Trial

(PresseBox) – BIOTRONIK has announced the start of enrollment of a coronary stent trial aiming at assessing the safety and clinical performance of a new coronary stent in de novo coronary artery lesions. On September 28, first Dr. Marco Moccetti, Cardiocentro Ticino, Lugano, Switzerland, and later on the same day Dr. Lorenz Raeber, University […]

Essential Medical Release: The MANTA Large Bore Vascular Closure Device To Be Evaluated In A 500-Patient European Post Market Clinical Registry

EXTON, Pennsylvania, Oct. 9, 2017 /PRNewswire/ –Essential Medical, Inc. today announced initiation of enrollment in a post market clinical registry in the regions where MANTA is commercially available. Principle Investigator Nicolas Van Mieghem, MD, PhD, Medical Director of the Department of Interventional Cardiology at Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands stated, “MANTA has quickly become […]

BioCardia Receives U.S. Patent Covering Morph Product Family Design

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure, today announced the issuance of United States Patent No. 9,775,963 entitled, “Steerable Endoluminal Devices and Methods.” BioCardia CEO Peter Altman, PhD stated, “This new patent […]

BioVentrix Announces First Patient Enrolled In The U.S. Arm Of IDE Study Of The Revivent TC TransCatheter Ventricular Enhancement Treatment

SAN RAMON, Calif., and PITTSBURGH, Pa., Oct. 4, 2017 /PRNewswire/ — BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced enrollment of the first patient in the U.S. arm of the ALIVE pivotal clinical trial. The trial is designed to demonstrate the safety and effectiveness […]

Study Shows Significant Link Between AMI and This Common Illness

By Ken Dropiewski, Prime-Core Executive Search ( Shingles are caused when the dormant Chickenpox virus reactivates. The result is an excruciatingly painful rash that causes inflammation of the underlying nerve tracks. This condition tends to develop at the most inopportune times such as during periods of stress and illness. It […]

Advanced Bifurcation Systems Announces Plan for Human Clinical Trials in New Brunswick, Canada

LOS ANGELES, Oct. 03, 2017 (GLOBE NEWSWIRE) — Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that the Company is planning to […]

Cathworks Lands $15.8 Million Series B Financing

KFAR SABA, Israel, Oct. 2nd, 2017 /PRNewswire/ — CathWorks Ltd., a leader in the development of non-invasive FFR measurements for guiding coronary interventions, today announced the completion of a $15.8M Series B round of financing, led by Quark Venture and Triventures. The syndicate also included Planven Investments, Pontifax, Corundum Open Innovation, and BioStar Venturesas well as a strategic investor. […]

Jeffrey H. Burbank Joins CryoLife Board of Directors

ATLANTA, Oct. 2, 2017 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced the appointment of Jeffrey H. Burbank to its Board of Directors effective September 29, 2017. Pat Mackin, Chairman, President, and Chief Executive Officer, commented, “Jeff has over 30 years of in-depth management […]